Literature DB >> 25617860

A concise review of non-alcoholic fatty liver disease.

Nwe Ni Than1, Philip N Newsome2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and the incidence of which is rising rapidly due to the increasing epidemic of obesity in both adults and children. The initial accumulation of fat followed by subsequent inflammation is central to the development of liver damage, and is critically influenced by host factors including age, gender, presence of diabetes, genetic polymorphisms and more recently by the gut microbiome. An increasing body of data suggest that NAFLD is also an independent risk factor of cardiovascular disease, which remains the commonest cause of mortality in such patients. This review focusses on the pathogenesis of NAFLD, and the evolution of new approaches to the management and treatment of NAFLD.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Dyslipidaemia; Insulin resistance; Non-alcoholic fatty liver disease; Pathogenesis

Mesh:

Substances:

Year:  2015        PMID: 25617860     DOI: 10.1016/j.atherosclerosis.2015.01.001

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  109 in total

1.  Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population.

Authors:  Elena Larrieta-Carrasco; Yvonne N Flores; Luis R Macías-Kauffer; Paula Ramírez-Palacios; Manuel Quiterio; Eric G Ramírez-Salazar; Paola León-Mimila; Berenice Rivera-Paredez; Guillermo Cabrera-Álvarez; Samuel Canizales-Quinteros; Zuo-Feng Zhang; Tania V López-Pérez; Jorge Salmerón; Rafael Velázquez-Cruz
Journal:  Exp Mol Pathol       Date:  2018-01-04       Impact factor: 3.362

Review 2.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 3.  Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems.

Authors:  David J Hughes; Tomasz Kostrzewski; Emma L Sceats
Journal:  Exp Biol Med (Maywood)       Date:  2017-05-15

4.  Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress.

Authors:  Tianhui Liu; Ping Wang; Min Cong; Xinyan Zhao; Dong Zhang; Hufeng Xu; Lin Liu; Jidong Jia; Hong You
Journal:  Br J Pharmacol       Date:  2018-10-23       Impact factor: 8.739

5.  Mortality disparities: A comparison with the Haudenosaunee in New York State.

Authors:  Rodney C Haring; Melissa A Jim; Deborah Erwin; Judith Kaur; Whitney Ann E Henry; Marissa L Haring; Dean S Seneca
Journal:  Cancer Health Disparities       Date:  2018-06-29

Review 6.  Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.

Authors:  Tyler J Severson; Siddesh Besur; Herbert L Bonkovsky
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

7.  GLP-1 receptor agonist on cardiovascular complications of diabetes mellitus.

Authors:  Fengjun Liu; Yanhua Kong
Journal:  Exp Ther Med       Date:  2020-01-20       Impact factor: 2.447

Review 8.  The Science of Obesity Management: An Endocrine Society Scientific Statement.

Authors:  George A Bray; William E Heisel; Ashkan Afshin; Michael D Jensen; William H Dietz; Michael Long; Robert F Kushner; Stephen R Daniels; Thomas A Wadden; Adam G Tsai; Frank B Hu; John M Jakicic; Donna H Ryan; Bruce M Wolfe; Thomas H Inge
Journal:  Endocr Rev       Date:  2018-04-01       Impact factor: 19.871

Review 9.  Role of cAMP and phosphodiesterase signaling in liver health and disease.

Authors:  Banrida Wahlang; Craig McClain; Shirish Barve; Leila Gobejishvili
Journal:  Cell Signal       Date:  2018-06-11       Impact factor: 4.315

Review 10.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.